Pegfilgrastim biosimilar - Qilu PharmaceuticalsAlternative Names: PEG-rhG-CSF
Latest Information Update: 06 May 2016
At a glance
- Originator Qilu Pharmaceutical
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 03 May 2016 Phase-III clinical trials in Neutropenia (Chemotherapy-induced) in China (unspecified route)
- 15 Mar 2016 Biomarkers information updated